article thumbnail

Impella Pump Improves Survival in STEMI-Related Cardiogenic Shock

Med Page Today

(MedPage Today) -- ATLANTA -- Routine use of the Impella CP microaxial flow pump significantly improved survival in patients with infarct-related cardiogenic shock, the randomized DanGer Shock trial showed. In more than 350 patients receiving.

article thumbnail

Cardiogenic Shock

American College of Cardiology

The goal of the DanGer Shock trial was to compare the safety and efficacy of Impella CP on top of standard care compared with standard care alone among patients with ST-segment elevation myocardial infarction (STEMI) and cardiogenic shock.

article thumbnail

DanGer Shock: Impella CP Improves Survival After STEMI With Cardiogenic Shock

American College of Cardiology

Implantation of the Impella CP micro-axial flow pump may increase survival at six months among patients with STEMI complicated by cardiogenic shock (CS), according to the results of the DanGer Shock study.

article thumbnail

How cardiogenic shock in NSTEMI is different from STEMI?

Dr. S. Venkatesan MD

Cardiogenic shock (CS)is the most feared event following STEMI. We tend to perceive CS as an exclusive complication of STEMI. The incidence is half of that of STEMI, i.e., 2.5-5%. might show little elevation with considerable overlap of left main STEMI vs NSTEMI ) 2.Onset How is CS in NSTEMI different ?

article thumbnail

Heart pump increases survival in STEMI-related cardiogenic shock

Nature Reviews - Cardiology

Nature Reviews Cardiology, Published online: 23 April 2024; doi:10.1038/s41569-024-01035-9 Data from the DanGer Shock trial demonstrate that implantation of a microaxial flow pump in patients with ST-segment elevation myocardial infarction complicated by cardiogenic shock increases the survival rate compared with standard care alone.

article thumbnail

Facility-based approach for the management of acute ST segment elevation myocardial infarction with cardiogenic shock in a rural medical centre: the Durango model

Open Heart

Introduction Cardiogenic shock (CS) complicates 5%–15% of cases of acute myocardial infarction (AMI) with inpatient mortality greater than 40%. This prospective registry includes all patients >18 years of age presenting with STEMI with or without CS beginning on 1 February 2023.

article thumbnail

DanGer Shock: Older Patients Exhibit Greater Risk of Mortality With Microaxial Flow Pump Treatment

American College of Cardiology

Older patients with STEMI-related cardiogenic shock have a greater risk of mortality and may not experience the same benefit from microaxial flow pump (mAFP) treatment as their younger counterparts, according to an exploratory secondary analysis of the DanGer Shock trial presented at AHA 2024 and simultaneously published in JACC.